Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Corticotropin-Releasing Factor Receptor Type 2 (CRFR2) is a G protein-coupled receptor that mediates the effects of corticotropin-releasing factor (CRF) and related peptides like Urocortin II and Urocortin III. It plays a crucial role in regulating stress responses, HPA axis function, serotonergic activity, angiogenesis, energy homeostasis, and thermoregulation. The receptor exhibits splice variants with distinct tissue distributions, impacting its diverse physiological functions and potential therapeutic applications in psychiatric, cardiovascular, and metabolic disorders.
Agonists (Urocortin II, Urocortin III, Corticotropin-releasing hormone) activate the receptor, leading to downstream signaling cascades. Antagonists inhibit receptor activation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Corticotropin-Releasing Factor Receptor Type 2 (CRFR2).